Medicine
Garzulys 100 IU/mL injection
Garzulys 100 IU/mL injection is a prescription medicine containing Insulin aspart for intravenous, subcutaneous use, marketed by Meitheal Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store unused Garzulys in a refrigerator between 2°C to 8°C (36°F to 46°F). Do…
Key facts
- Active ingredient (INN)
- Insulin aspart
- Brand
- Garzulys
- Strength
- 100 IU/mL
- Dosage form
- Injection
- Route
- Intravenous, subcutaneous
- Packs
- 1 vial
- Marketing authorisation holder
- Meitheal Pharmaceuticals
- Manufacturer
- Meitheal Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store unused Garzulys in a refrigerator between 2°C to 8°C (36°F to 46°F). Do not freeze Garzulys and do not use Garzulys if it has been frozen. Storage Conditions for Garzulys Vial and Prefilled Pen Garzulys presentation Not in-use (unopened) Room Temperature (up to 30°C [86°F]) Not in-use (unopened) Refrigerated (2°C to 8°C [36°F to 46°F]) In-use (opened) Room Temperature (up to 30°C [86°F]) 10…
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A10AB05 Insulin aspart
- HS code (indicative)
- 3004.31Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 24 July 2026
- Identifiers
- RxCUI 2748451, 2748457, 2748459 +1DailyMed set ID 30c64769-d2f7-4604-ac9e-2a6bc09506c9NDC 71288-904Application BLA761497
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, glass in 1 carton / 10 mL in 1 vial, glass | 71288-904-10 | Meitheal Pharmaceuticals | 24 July 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Insulin aspart 100 IU/mL injection.
- Novolog 100 IU/mL injectionAvailable on requestNovo NordiskUS FDA8 packs Cold chain
- Insulin aspart 100 IU/mL injectionAvailable on request—US FDA6 packs Cold chain
- Fiasp 100 IU/mL injectionAvailable on requestNovo NordiskUS FDA4 packs Cold chain
- Kirsty 100 IU/mL injectionAvailable on requestBiocon BiologicsIndiaUS FDA2 packs Cold chain
- Merilog 100 IU/mL injectionAvailable on requestSanofi-AventisUS FDA2 packs Cold chain
- Garzulys 100 IU/mL injectionAvailable on requestMeitheal PharmaceuticalsUS FDA1 pack Cold chain
Other strengths and forms of Insulin aspart
Clinical summary
Insulin aspart is an insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. It is available as injection and injectable suspension for subcutaneous and intravenous use. MedsAcross supplies Insulin aspart for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Insulin aspartFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Fiasp prescribing information (Novo Nordisk) · U.S. National Library of Medicine, DailyMed
- Fiasp: European public assessment report (EPAR) · European Medicines Agency
- NovoMix: European public assessment report (EPAR) · European Medicines Agency
Need Garzulys 100 IU/mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.